We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Candidate Cancer Drug Blocks Growth and Reverses Drug Resistance

By LabMedica International staff writers
Posted on 09 Oct 2018
A candidate drug for treatment of pancreatic cancer was shown to slow growth and spread of the disease in cell cultures and reverse drug resistance in preclinical animal models.

Growth, progression, and drug resistance of pancreatic ductal adenocarcinomas (PDACs) have been associated with increased levels and activity of the enzymes glycogen synthase kinase 3 beta (GSK3B) and histone deacetylases (HCACs). More...
GSK-3B stimulates proliferation and resistance to apoptosis in cancer cells while HDAC inhibits epithelial cells. A drug that inhibits these two enzymes should simultaneously affect proliferation and metastasis.

The drug candidate, Metavert, is a small molecular dual inhibitor that blocks two pro-cancer pathways through two linked moieties that target GSK3B and HDAC. In a study published in the August 22, 2018, online edition of the journal Gastroenterology, investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) - who hold a patent on the drug - tested its effects in pancreatic cancer cells and mice with pancreatic tumors.

The investigators tested the ability of Metavert to bind GSK3B and HDACs in various cell lines using surface plasmon resonance. Plasmon resonance is a phenomenon that occurs when light is reflected off thin metal films, which may be used to measure interaction of biomolecules on the surface. An electron charge density wave arises at the surface of the film when light is reflected at the film under specific conditions. A fraction of the light energy incident at a defined angle can interact with the delocalized electrons in the metal film (plasmon) thus reducing the reflected light intensity. The angle of incidence at which this occurs is influenced by the refractive index close to the backside of the metal film, to which target molecules are immobilized. If ligands in a mobile phase running along a flow cell bind to the surface molecules, the local refractive index changes in proportion to the mass being immobilized. This can be monitored in real time by detecting changes in the intensity of the reflected light.

Treated cells were analyzed for apoptosis and migration and by immunoblotting, immunofluorescence, and real-time PCR. Normal mice were given injections of Metavert or vehicle (control). B6.129J mice with tumors grown from UN-KPC961-Luc cells were given injections of Metavert or vehicle. Tumors and metastases were counted and pancreata were analyzed by immunohistochemistry. Glucose metabolism was measured using 13C-glucose tracer and mass spectroscopy and flow cytometry.

Results revealed that Metavert significantly reduced survival of PDAC cells but not non-transformed cells. The drug reduced markers of the epithelial to mesenchymal transition and stem cells in PDAC cell lines. Cells incubated with Metavert in combination with irradiation and the chemotherapeutic agent paclitaxel or gemcitabine had reduced survival compared to cells incubated with either agent alone. Metavert increased killing of drug-resistant PDAC cells by paclitaxel and gemcitabine. In addition, PDAC cells incubated with Metavert acquired normalized glucose metabolism.

Administration of Metavert (alone or in combination with gemcitibine) to mice with syngeneic tumors significantly increased their survival times, slowed tumor growth, prevented tumor metastasis, decreased tumor infiltration by tumor-associated macrophages, and decreased blood levels of cytokines.

"This is an exciting step toward improving survival rates in pancreatic cancer patients," said first author Dr. Mouad Edderkaoui, assistant professor of medicine and biomedical sciences at Cedars-Sinai Medical Center. "If the results are confirmed in humans, we could have a drug with the potential to significantly extend the lives of patients with pancreatic ductal adenocarcinoma (PDAC), which is very difficult to treat."

Related Links:
Cedars-Sinai Medical Center

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.